Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

INTRODUCTION: Neoadjuvant chemotherapy for breast cancer treatment is prescribed to facilitate surgery and provide confirmation of drug-sensitive disease, and the achievement of pathological complete response (pCR) predicts improved long-term outcomes. Docosahexaenoic acid (DHA) has been shown to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Newell, Marnie, Mackey, John R, Bigras, Gilbert, Alvarez-Camacho, Mirey, Goruk, Susan, Ghosh, Sunita, Schmidt, Alison, Miede, Deborah, Chisotti, Ann, Postovit, Lynne, Baker, Kristi, Mazurak, Vera, Courneya, Kerry, Berendt, Richard, Dong, Wei-Feng, Wood, George, Basi, Sanraj K, Joy, Anil Abraham, King, Karen, Meza-Junco, Judith, Zhu, Xiaofu, Field, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756327/
https://www.ncbi.nlm.nih.gov/pubmed/31530611
http://dx.doi.org/10.1136/bmjopen-2019-030502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756327/
https://www.ncbi.nlm.nih.gov/pubmed/31530611
http://dx.doi.org/10.1136/bmjopen-2019-030502

Ejemplares similares